Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It …
Medical - Diagnostics & Research
US, Wilmington [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 58.04 | 73.05 | 46.22 | |
| Graham Fair Price | -39.80 | 45.66 | 75.83 | |
| PEG | 499.40 | -0.85 | 0.14 | |
| Price/Book | 13.52 | 3.83 | 3.37 | |
| Price/Cash Flow | 222.93 | 274.65 | 85.05 | |
| Prices/Earnings | 219.26 | 51.75 | 16.21 | |
| Price/Sales | 15.11 | 13.78 | 11.97 | |
| Price/FCF | 222.93 | 274.65 | 85.05 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -11.89 | 0.32 | 0.36 | |
| Operating Margin | 7.77 | 0.14 | 0.13 | |
| ROA | -63.82 | < 0.005 | 0.02 | |
| ROE | 0.05 | 0.02 | -64.44 | |
| ROIC | 0.02 | 0.02 | 1.18 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | < 0.005 | 0.06 | -91.35 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.12 | 0.08 | -38.32 | |
| EPS QOQ | 1.15 | -0.61 | -46.74 | |
| FCF QOQ | 0.02 | -0.64 | 2783.16 | |
| Revenue QOQ | -0.01 | < 0.005 | 85.24 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 52.70 | 47.03 | -10.76 | |
| Days Sales Outstanding (DSO) | 69.30 | 70.02 | 1.04 | |
| Inventory Turnover | 1.71 | 1.91 | 12.06 | |
| Debt/Capitalization | 0.49 | 0.42 | -14.95 | |
| Quick Ratio | 1.00 | 1.18 | 17.53 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 70.10 | 70.77 | 0.96 | |
| Cash | 5.39 | 6.56 | 21.59 | |
| Capex | -1.53 | -1.54 | -0.80 | |
| Free Cash Flow | 2.78 | 0.99 | -64.51 | |
| Revenue | 19.75 | 19.67 | -0.43 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Weak